BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 16782190)

  • 1. Tumour lysis syndrome with acute renal failure during imatinib therapy.
    Ali R; Ozkalemkas F; Ozkan A; Ozcelik T; Ozkocaman V; Akdag I; Ozan U; Tunali A
    Leuk Res; 2007 Apr; 31(4):573-4. PubMed ID: 16782190
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia.
    Al-Kali A; Farooq S; Tfayli A
    J Clin Pharm Ther; 2009 Oct; 34(5):607-10. PubMed ID: 19744017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.
    François H; Coppo P; Hayman JP; Fouqueray B; Mougenot B; Ronco P
    Am J Kidney Dis; 2008 Feb; 51(2):298-301. PubMed ID: 18215707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib-induced tumor lysis syndrome: report of a case and review of the literature.
    Chang H; Shih LY
    Chang Gung Med J; 2008; 31(5):510-4. PubMed ID: 19097599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate induced skin hypopigmentation.
    Talwar V; Doval DC; Bhatia K
    J Assoc Physicians India; 2007 Jul; 55():527. PubMed ID: 17907508
    [No Abstract]   [Full Text] [Related]  

  • 6. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
    J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there any protective effect on organs upon higher uric acid level in tumor lysis syndrome?
    Basturk A; Hacibekiroglu T; Akinci S; Dilek I; Atalay HV
    Ren Fail; 2011; 33(4):465. PubMed ID: 21529279
    [No Abstract]   [Full Text] [Related]  

  • 8. Imatinib and pregnancy.
    Ali R; Ozkalemkas F; Ozcelik T; Ozkocaman V; Ozkan A
    J Clin Oncol; 2006 Aug; 24(23):3812-3; author reply 3813. PubMed ID: 16896012
    [No Abstract]   [Full Text] [Related]  

  • 9. Primary ovarian insufficiency associated with imatinib therapy.
    Christopoulos C; Dimakopoulou V; Rotas E
    N Engl J Med; 2008 Mar; 358(10):1079-80. PubMed ID: 18322295
    [No Abstract]   [Full Text] [Related]  

  • 10. Peripheral neuropathy as an adverse effect of imatinib therapy.
    Chakupurakal G; Etti RJ; Murray JA
    J Clin Pathol; 2011 May; 64(5):456. PubMed ID: 21278395
    [No Abstract]   [Full Text] [Related]  

  • 11. Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib.
    Woo SM; Huh CH; Park KC; Youn SW
    J Dermatol; 2007 Oct; 34(10):724-6. PubMed ID: 17908148
    [No Abstract]   [Full Text] [Related]  

  • 12. Multiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia.
    Galanopoulos A; Papadhimitriou SI; Kritikou-Griva E; Georgiakaki M; Anagnostopoulos NI
    Ann Hematol; 2009 Mar; 88(3):281-2. PubMed ID: 18726593
    [No Abstract]   [Full Text] [Related]  

  • 13. Challenging problems in advanced malignancy: Case 3. Imatinib mesylate-induced interstitial pneumonitis.
    Rosado MF; Donna E; Ahn YS
    J Clin Oncol; 2003 Aug; 21(16):3171-3. PubMed ID: 12915610
    [No Abstract]   [Full Text] [Related]  

  • 14. Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection.
    Thia TJ; Tan HH; Chuah TH; Chow WC; Lui HF
    Singapore Med J; 2008 Mar; 49(3):e86-9. PubMed ID: 18362995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Catastrophic tumour lysis syndrome following single dose of imatinib.
    Keane C; Henden A; Bird R
    Eur J Haematol; 2009 Mar; 82(3):244-5. PubMed ID: 19067739
    [No Abstract]   [Full Text] [Related]  

  • 16. Neutrophilic eccrine hidradenitis induced by imatinib mesylate (Gleevec) therapy.
    Dib EG; Ifthikharuddin JJ; Scott GA; Partilo SR
    Leuk Res; 2005 Feb; 29(2):233-4. PubMed ID: 15607374
    [No Abstract]   [Full Text] [Related]  

  • 17. Imatinib-lnduced agranulocytosis in a patient with chronic myelogenous leukemia in remission.
    Khouri S; Kotliroff A; Lishner M; Amital H
    Isr Med Assoc J; 2008 Apr; 10(4):320-1. PubMed ID: 18548994
    [No Abstract]   [Full Text] [Related]  

  • 18. Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib.
    Breccia M; D'Elia GM; D'Andrea M; Latagliata R; Alimena G
    Eur J Haematol; 2005 Jan; 74(1):89-90. PubMed ID: 15613116
    [No Abstract]   [Full Text] [Related]  

  • 19. Cutaneous reactions to STI571.
    Brouard M; Saurat JH
    N Engl J Med; 2001 Aug; 345(8):618-9. PubMed ID: 11529225
    [No Abstract]   [Full Text] [Related]  

  • 20. Imatinib-induced erythrodermia in a patient with chronic myeloid leukemia.
    Oztas P; Erbasi S; Lenk N; Polat M; Han O; Artuz F; Alli N
    Acta Derm Venereol; 2006; 86(2):174-5. PubMed ID: 16648930
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.